Cell culture medium is generally considered as the most expensive consumable in upstream continuous processes. Performing high cell density perfusion processes that are economically sustainable from clinical to manufacturing scales require a good understanding of the process and the metabolic requirements of the cells in order to minimize perfusion rates while maintaining the desired cell density, productivity and product quality profile.
However, cell culture medium performance and its economics are not the only criteria to be considered when selecting the preferred supplier. Manufacturers need to be able to ensure business continuity for clinical and manufacturing processes, which depends greatly on the supplier’s supply chain sustainability and robustness as well as manufacturing capabilities and consistency.
In this webinar, we will:
- Provide an overview on current industry trends in the context of intensified processes
- Show the economic benefits when using a cell culture medium designed specifically for perfusion processes
- Discuss proactive risk measures suppliers need to take to facilitate the manufacturer’s business continuity and product quality